Zoledronate to help prevent Paget’s disease over time
Part of Bones, joints & muscles clinical trials.
This trial is a long-term follow-up for people who already took part in a previous study called ZiPP. It tests whether continuing treatment with zoledronate can help prevent Paget’s disease from developing or worsening.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You took part in the earlier ZiPP study
- You are willing and able to sign an informed consent form
- You are willing and able to follow the study plan and visit schedule
- You must be able to understand the study well enough to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if it's safe to switch from a long-term osteoporosis medication called Prolia to another treatment. It may help women and men who have been on Prolia for at least 3 years.
This trial studies how the drug zoledronic acid (used for bone loss) works in people with kidney disease who are on dialysis. It aims to help treat osteoporosis (weak bones) safely in this group.
This trial tests whether giving zoledronic acid (a bone-strengthening infusion) right after stopping denosumab can help prevent bone loss in women with post-menopausal osteoporosis. It may be a good option if you have finished at least 2 years of denosumab and your doctor says it's safe to stop.
This study compares two medicines (ibandronate and zoledronic acid) to see which one works better at keeping bones strong after stopping denosumab (Prolia). It's for postmenopausal women with mild to moderate bone thinning.
This trial tests if a bone-strengthening drug called zoledronic acid can help people with congenital dyserythropoietic anemia (CDA), a rare type of anemia. It's for adults with moderate to severe anemia who may also need blood transfusions.
This study tests whether zoledronic acid, a medicine given by IV, helps prevent bone problems in women with breast cancer that has spread to the bones. It looks at how well the drug works in a real-world setting to reduce the risk of fractures or other bone issues.
Hear when a new Paget Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.